Integra Lifesciences Holdings CORP Form 4 insider transactions

Director Shaundra Clay reports acquiring 19,592 shares of Integra LifeSciences common stock and disposing of 41,515 shares in a recent transaction.

Director Barbara Hill reports acquisition of Integra LifeSciences Holdings Corp shares through previously awarded stock.

Director Lo Renee Wonlai reports acquisition and disposal of Integra LifeSciences Holdings Corp shares on May 9, 2025.

Director Christian S. Schade reports acquisition of Integra LifeSciences Holdings Corp stock through non-open market transactions.

Stuart Essig, Executive Chairman of Integra LifeSciences, reports the acquisition of shares through a Grantor Retained Annuity Trust (GRAT) and updates beneficial ownership.

Eric Schwartz, EVP, Chief Legal Officer & Secretary of Integra LifeSciences, reports disposition of common stock to cover tax obligations.

EVP & CFO Lea Daniels Knight reports acquisition and disposal of Integra LifeSciences Holdings Corp stock and stock options on March 11, 2025.

Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer of Integra LifeSciences, reports acquisition and disposal of company stock on March 11, 2025.

EVP & President, CSS, Michael J. McBreen, reports acquisition and disposal of Integra LifeSciences Holdings Corp stock and stock options on March 11, 2025.

Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences, reports acquisition and disposal of company stock and stock options.

Robert T. Davis Jr., EVP & President, TT, of Integra LifeSciences Holdings Corp, reports acquisition and disposal of common stock and stock options.

EVP & President, International, Harvinder Singh, reports transactions involving Integra LifeSciences Holdings Corp. stock, including the vesting of restricted stock units and stock options.

Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer of Integra LifeSciences, reports the disposal of common stock to cover tax obligations.

Michael J. McBreen, EVP & President of CSS at Integra LifeSciences, reports the disposal of common stock to cover tax obligations.

Eric Schwartz, EVP, Chief Legal Officer & Secretary of Integra LifeSciences, reported disposing of 773 shares of common stock to cover tax obligations.

Robert T. Davis Jr., EVP & President, TT of Integra LifeSciences Holdings Corp, disposed of 592 shares of common stock on March 10, 2025, to cover tax obligations.

EVP & President, International, Harvinder Singh, reports the vesting and disposal of Integra LifeSciences Holdings Corp stock units.

Poul Mojdeh, President & CEO of Integra LifeSciences, reports the acquisition of stock options and restricted stock units.

Eric Schwartz, EVP, Chief Legal Officer & Secretary of Integra LifeSciences, sold 4,070 shares of common stock on December 3, 2024.

Michael J. McBreen, an executive at Integra LifeSciences, sold 1,700 shares of common stock at a price of $24.155 per share on December 2, 2024.

CEO Jan De Witte reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences, reports disposing of 1,412 shares of common stock on September 1, 2024, to cover tax obligations.

Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer of Integra LifeSciences Holdings Corp, sold 1,191 shares of common stock on August 19, 2024.

Lea Daniels Knight, EVP & CFO of Integra LifeSciences, reported disposing of 2,561 shares of common stock on July 3, 2024, to cover tax obligations.

Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer of Integra LifeSciences, reports acquisition and disposal of common stock on July 1, 2024.

Stuart Essig, Executive Chairman of Integra LifeSciences, reports the acquisition and disposition of company stock, including a contribution of 500,000 shares to a Grantor Retained Annuity Trust.

Director Barbara Hill reports purchasing 36,350 shares of Integra LifeSciences Holdings Corp (IART) at an average price of $27.3952 on May 21, 2024.

Stuart Essig, Executive Chairman of Integra LifeSciences, reports acquisition of shares through non-open market transactions.

Director Shaundra Clay reports acquiring and disposing of Integra LifeSciences common stock on May 9, 2024.

Jeffrey A. Graves, a director at Integra LifeSciences, reported the acquisition and disposal of common stock on May 9, 2024.